TBG Diagnostics Ltd Competitors

Kancera is a clinical stage biotech developing a new class of small molecule drugs with an immune cell modulating mode-of-action with focus on cardiovascular diseases. The lead program KAND567 is in clinical phase II-stage and is aiming to prevent reperfusion injury that may occur in connection with percutaneous coronary intervention in acute myocardial infarction. The stock is traded on the Nasdaq First North Premier Growth Market.

Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production teams have extensive experience in drug discovery, medicinal chemistry, cell biology and experimental oncology.

Meditech is an Australian biotechnology company focused on developing and commercialising drugs that improve the health and quality of life of patients with cancer and other chronic diseases. The company has internationally recognised expertise in carbohydrate-based therapies, particularly products based upon the glycosaminoglycan, hyaluronic acid. Building on this expertise, Meditech has created its patented HyACTTM (Hyaluronic Acid Chemotransport Technology) platform which it is applying to the development of improved formulations of cancer drugs. The lead product from the HyACTÔ platform is HyCAMPÔ. In addition to HyCAMPTM, Meditech has taken the anti-cancer products HyDOXTM (doxorubicin and hyaluronic acid) and HyFIVETM (5-fluorouracil and hyaluronic acid) into clinical testing.